Alzheimer’s Research UK

Dementia Consortium funds dementia treatments team

Wednesday, March 15, 2017

The Dementia Consortium, a public-private partnership initiative bridging the gap between academic research and the pharmaceutical industry, is supporting a project led by Dr. David Brough at the University of Manchester to develop novel therapeutics for Alzheimer’s disease targeting the immune system. This is the fifth project supported by the Dementia Consortium, and has been awarded £191,757 by the initiative.

[Read More]

$100M Dementia Discovery Fund launches

Wednesday, October 21, 2015

The Dementia Discovery Fund, a new initiative designed to speed up the discovery and development of new treatments for dementia, has launched after securing $100 million backing from worldwide investors. The U.K. government’s Department of Health, Alzheimer’s Research U.K. and pharmaceutical companies including Biogen, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Pfizer and Takeda have joined forces to support the innovative new fund.

[Read More]

Alzheimer’s Research U.K. launches three Drug Discovery Institutes

Wednesday, February 18, 2015

Alzheimer’s Research U.K., a dedicated dementia research charity, has announced a $46.3 million Drug Discovery Alliance, launching three flagship Drug Discovery Institutes at the Universities of CambridgeOxford and University College London (UCL). The Drug Discovery Institutes will see 90 new research scientists employed in state-of-the-art facilities to fast-track the development of new treatments for Alzheimer’s disease and other dementias.

[Read More]

Neuro-MAP, MRC Technology to jumpstart drug development for brain diseases

Wednesday, November 19, 2014

Drugs for brain diseases such as dementia, motor neurone disease and Parkinson’s, which have stalled in development, could be revived thanks to up to $47.1 million in funding and resources from a global coalition of charities and funders. The Neurodegeneration Medicines Acceleration Program (Neuro-MAP), led by U.K. medical research charity MRC Technology, will help charities and funding bodies identify promising drug projects no longer in development and help scientists take them forward to the next stage.

[Read More]

Alzheimer’s Research U.K. calls for increased investment in Alzheimer’s drug trials

Monday, July 7, 2014

Alzheimer’s Research U.K. calls for increased investment in Alzheimer’s drug trials after a comprehensive study of all of the clinical trials for Alzheimer’s drugs in the U.S. highlighted a very high failure rate of the drugs being tested. The study, published in Alzheimer’s Research and Therapy, found that 99.6% of trials of potential Alzheimer’s treatments aimed at preventing, curing or improving the symptoms of the disease failed or were discontinued.

[Read More]

Report: U.K. a leader in dementia research

Thursday, March 22, 2012

The quality of dementia research in the U.K. is second only to the U.S., despite the low number of scientists working in this field, and finding a cure can be accelerated by increasing the number of dementia researchers and investment, according the Intellectual Property & Science business of Thomson Reuters. The findings are featured in an Alzheimer’s U.K. research report “Defeating Dementia.”

[Read More]